Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FosD · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| FosD | EXPERIMENTAL | Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects |
| Placebo | PLACEBO_COMPARATOR | Placebo given (2 subjects in each cohort) |
| Name | Type | Description |
|---|---|---|
| FosD | DRUG | oral tablet |
| Placebo | DRUG | oral tablet |
Inclusion Criteria: * Healthy male and female (of non-childbearing potential) Japanese subjects and White subjects (origins in Europe, the Middle East, or North Africa) * Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 45 kg and no more than 100 kg Exclusion Criteria: * History o...
FosD is an investigational small molecule being developed by AstraZeneca PLC (AZN). It is being studied in a Phase 1 clinical trial to assess its safety, tolerability, and blood and urine drug levels in healthy Japanese and White subjects. FosD is not approved and remains in clinical development.
FosD is being studied for use in healthy volunteers. The Phase 1 trial is designed to evaluate the safety, tolerability, and pharmacokinetics of FosD in healthy Japanese and White subjects. It is not being studied for a specific disease indication at this stage.
FosD is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting a Phase 1 clinical trial to evaluate the safety and tolerability of FosD in healthy subjects.
FosD is in Phase 1 clinical development. The completed trial, NCT01167868, was a Phase 1 study that assessed the safety, tolerability, and blood and urine drug levels of FosD in healthy Japanese and White subjects. FosD is investigational and not yet approved.
FosD has one completed clinical trial, NCT01167868, titled "A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects." This Phase 1 trial enrolled 56 participants in the United States and was placebo-controlled and double-blind.
Yes, FosD is an abbreviation for Fostamatinib Disodium. The clinical trial NCT01167868 refers to the drug as Fostamatinib Disodium (FosD), indicating that FosD is the short name for this compound. The trial evaluated its safety and tolerability in healthy subjects.